Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis: Relation to response and survival

M. De Lena, A. Romero, M. Rabinovich, B. Leone, C. Vallejo, M. Machiavelli, M. Cuevas, R. Rodriguez, J. Lacava, J. Perez, A. Barletta, A. Paradiso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.

Original languageEnglish
Pages (from-to)245-249
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number3
Publication statusPublished - 1993

Fingerprint

Ploidies
Breast Neoplasms
Neoplasm Metastasis
Survival
DNA
Aneuploidy
Bone and Bones
Flow Cytometry
Neoplasms
Diploidy
Reaction Time
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis : Relation to response and survival. / De Lena, M.; Romero, A.; Rabinovich, M.; Leone, B.; Vallejo, C.; Machiavelli, M.; Cuevas, M.; Rodriguez, R.; Lacava, J.; Perez, J.; Barletta, A.; Paradiso, A.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 3, 1993, p. 245-249.

Research output: Contribution to journalArticle

De Lena, M, Romero, A, Rabinovich, M, Leone, B, Vallejo, C, Machiavelli, M, Cuevas, M, Rodriguez, R, Lacava, J, Perez, J, Barletta, A & Paradiso, A 1993, 'Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis: Relation to response and survival', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 16, no. 3, pp. 245-249.
De Lena, M. ; Romero, A. ; Rabinovich, M. ; Leone, B. ; Vallejo, C. ; Machiavelli, M. ; Cuevas, M. ; Rodriguez, R. ; Lacava, J. ; Perez, J. ; Barletta, A. ; Paradiso, A. / Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis : Relation to response and survival. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1993 ; Vol. 16, No. 3. pp. 245-249.
@article{24bff5079e7e4d7cb5231a3f3b140515,
title = "Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis: Relation to response and survival",
abstract = "Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75{\%}; bone-only metastases (BM): 60{\%}; extraosseous-only metastases (EM): 40{\%}. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58{\%} and 68{\%} for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1{\%}. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.",
author = "{De Lena}, M. and A. Romero and M. Rabinovich and B. Leone and C. Vallejo and M. Machiavelli and M. Cuevas and R. Rodriguez and J. Lacava and J. Perez and A. Barletta and A. Paradiso",
year = "1993",
language = "English",
volume = "16",
pages = "245--249",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis

T2 - Relation to response and survival

AU - De Lena, M.

AU - Romero, A.

AU - Rabinovich, M.

AU - Leone, B.

AU - Vallejo, C.

AU - Machiavelli, M.

AU - Cuevas, M.

AU - Rodriguez, R.

AU - Lacava, J.

AU - Perez, J.

AU - Barletta, A.

AU - Paradiso, A.

PY - 1993

Y1 - 1993

N2 - Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.

AB - Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.

UR - http://www.scopus.com/inward/record.url?scp=0027230157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027230157&partnerID=8YFLogxK

M3 - Article

C2 - 8338059

AN - SCOPUS:0027230157

VL - 16

SP - 245

EP - 249

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -